Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5350775 | 0.79 | MTNR1A (0.51) | MTNR1ANQO2NPC1ALDH1A1LMNA | |
| SCHEMBL5341959 | 0.78 | MEN1 (0.47) | MTNR1ANPC1ALDH1A1 | |
| SCHEMBL5349751 | 0.78 | MTNR1A (0.43) | MTNR1ANQO2NPC1HPGDALDH1A1 | |
| SCHEMBL8693941 | 0.78 | MTNR1A (0.62) | MTNR1ANQO2HPGDALDH1A1 | |
| SCHEMBL6075810 | 0.72 | GHSR (0.44) | MTNR1ANPC1ALDH1A1 | |
| SCHEMBL24821344 | 0.72 | NPC1 (0.54) | NPC1HPGD | |
| SCHEMBL6076617 | 0.69 | CCNA2 (0.37) | MTNR1ANQO2NPC1ALDH1A1 | |
| SCHEMBL6078099 | 0.68 | CCNA2 (0.36) | MTNR1ANPC1ALDH1A1 | |
| SCHEMBL14052528 | 0.66 | HPGD (0.64) | NPC1HPGDTDP1ALDH1A1LMNA | |
| SCHEMBL8693024 | 0.66 | MTNR1A (0.65) | MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | disclosed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | MTNR1A 388/4885NQO2 492/4885NPC1 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.